The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to the Anovo robotic surgery platform, developed by Momentis Surgical, for repairing ventral hernias. This approval expands the platform's utility beyond its existing FDA clearances for transvaginal gynecological procedures.
Anovo is distinguished as the only robotic platform globally approved by the FDA for minimally invasive abdominal hernia repair using just a single entry incision. The system features robotic arms that mimic human arms, equipped with joints capable of 360-degree rotation and flexibility across multiple planes. This design allows for the insertion of several surgical instruments through a single entry point, enhancing maneuverability and potentially reducing invasiveness.
Unique Robotic Technology
Professor Yoav Mintz from Hadassah Medical Center highlighted the unique approach of the Momentis robot, stating, "The Momentis robot offers a unique approach to robotic surgery. The flexible arms combined with a single entry point enhance maneuverability while ensuring a less invasive procedure."
The Anovo system is designed to be compact and mobile, making it suitable for use in both hospitals and physician clinics. This broader applicability aims to improve surgical outcomes, reduce costs, and increase access to robotic-assisted surgeries.
Company Focus
Momentis Surgical focuses on developing miniaturized robotic technologies for a range of medical applications. Dvir Cohen, CEO and co-founder of Momentis, noted, "We leveraged the clinical success of the Anovo platform in gynecology to expand into general surgery. Its size and mobility make the system suitable for both hospitals and physician clinics."
Dr. Frederic H. Moll, a member of the Momentis board of directors, commented, "The company has now created a true robotic platform, making it a distinctive technology that will have an immediate impact on the way general surgery is performed."
